25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NRXP (NRX Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze NRX Pharmaceuticals Inc together

I guess you are interested in NRX Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – NRX Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – NRX Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of NRX Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about NRX Pharmaceuticals Inc

I send you an email if I find something interesting about NRX Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of NRX Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of NRX Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
3.3%

What is your share worth?

Current worth
$-1.46
Expected worth in 1 year
$-2.04
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
$-0.58
Return On Investment
-17.3%

For what price can you sell your share?

Current Price per Share
$3.38
Expected price per share
$2.41 - $6
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of NRX Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$3.38
Intrinsic Value Per Share
$-5.81 - $-6.76
Total Value Per Share
$-7.26 - $-8.22

2.2. Growth of NRX Pharmaceuticals Inc (5 min.)




Is NRX Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$25.1m-$8.9m-$12.4m-58.1%

How much money is NRX Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$6m-$6.4m$382.2k6.3%
Net Profit Margin-91,187.5%-33,937.5%--

How much money comes from the company's main activities?

2.3. Financial Health of NRX Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#843 / 884

Most Revenue
#643 / 884

Most Profit
#450 / 884

Most Efficient
#875 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of NRX Pharmaceuticals Inc?

Welcome investor! NRX Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of NRX Pharmaceuticals Inc.

First you should know what it really means to hold a share of NRX Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of NRX Pharmaceuticals Inc is $3.38. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of NRX Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in NRX Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.46. Based on the TTM, the Book Value Change Per Share is $-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of NRX Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.32-9.4%-0.35-10.3%-0.16-4.6%-0.21-6.2%-0.54-16.1%-0.36-10.8%
Usd Book Value Change Per Share-0.11-3.3%-0.15-4.3%-0.22-6.4%-0.16-4.8%-0.08-2.5%-0.05-1.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.041.1%0.020.7%
Usd Total Gains Per Share-0.11-3.3%-0.15-4.3%-0.22-6.4%-0.16-4.8%-0.05-1.4%-0.02-0.7%
Usd Price Per Share2.05-2.10-0.42-1.10-6.12-7.49-
Price to Earnings Ratio-1.61--2.12--1.11--1.66--76.37--963.35-
Price-to-Total Gains Ratio-18.29--26.86--7.24--13.40--26.19--444.55-
Price to Book Ratio-1.41--1.72--4.97--14.07-63.89-46.24-
Price-to-Total Gains Ratio-18.29--26.86--7.24--13.40--26.19--444.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.38
Number of shares295
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.04
Usd Book Value Change Per Share-0.15-0.08
Usd Total Gains Per Share-0.15-0.05
Gains per Quarter (295 shares)-43.05-13.71
Gains per Year (295 shares)-172.20-54.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-172-18244-99-65
20-344-35488-197-120
30-517-526132-296-175
40-689-698176-395-230
50-861-870219-494-285
60-1033-1042263-592-340
70-1205-1214307-691-395
80-1378-1386351-790-450
90-1550-1558395-889-505
100-1722-1730439-987-560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%6.024.00.020.0%6.024.00.020.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%9.021.00.030.0%9.021.00.030.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%1.00.029.03.3%1.00.029.03.3%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%5.015.00.025.0%10.020.00.033.3%10.020.00.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of NRX Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.112-0.146+30%-0.217+93%-0.163+45%-0.084-25%-0.049-57%
Book Value Per Share---1.455-1.238-15%-0.281-81%-0.444-69%-0.213-85%0.776-288%
Current Ratio--0.2220.195+13%0.523-58%1.098-80%1.114-80%1.182-81%
Debt To Asset Ratio--4.3155.347-19%2.550+69%2.821+53%1.955+121%1.353+219%
Debt To Equity Ratio----0%-0%0.270-100%0.739-100%0.928-100%
Dividend Per Share----0%-0%-0%0.037-100%0.025-100%
Enterprise Value--8239860.00012213624.000-33%13361235.638-38%27740670.599-70%209626735.470-96%2497284900.012-100%
Eps---0.319-0.349+9%-0.156-51%-0.209-34%-0.544+71%-0.365+14%
Ev To Ebitda Ratio---0.374-0.634+70%-0.562+50%-0.931+149%-11.608+3006%-4945.397+1323176%
Ev To Sales Ratio--514.991651.409-21%230.820+123%441.115+17%441.115+17%441.115+17%
Free Cash Flow Per Share---0.201-0.165-18%-0.103-49%-0.134-33%-0.131-35%-0.090-55%
Free Cash Flow To Equity Per Share--0.2370.048+400%-0.084+135%-0.042+118%-0.062+126%0.016+1404%
Gross Profit Margin--1.0001.000+0%1.000+0%1.000+0%23.423-96%16.505-94%
Intrinsic Value_10Y_max---6.762----------
Intrinsic Value_10Y_min---5.808----------
Intrinsic Value_1Y_max---0.557----------
Intrinsic Value_1Y_min---0.547----------
Intrinsic Value_3Y_max---1.765----------
Intrinsic Value_3Y_min---1.683----------
Intrinsic Value_5Y_max---3.084----------
Intrinsic Value_5Y_min---2.855----------
Market Cap58437496.000+39%35442860.00036220874.000-2%25877235.638+37%37934837.265-7%215114446.966-84%202440723.178-82%
Net Profit Margin---1378.000-911.875-34%-339.375-75%-417.083-70%-250.250-82%-166.833-88%
Operating Margin---2269.500-1134.750-50%-335.838-85%-490.196-78%-294.118-87%-196.078-91%
Operating Ratio--962.250392.688+145%325.125+196%239.271+302%143.563+570%95.708+905%
Pb Ratio-2.323-65%-1.409-1.723+22%-4.970+253%-14.071+899%63.892-102%46.243-103%
Pe Ratio-2.650-65%-1.608-2.123+32%-1.109-31%-1.660+3%-76.368+4651%-963.350+59827%
Price Per Share3.380+39%2.0502.095-2%0.419+389%1.097+87%6.117-66%7.492-73%
Price To Free Cash Flow Ratio-4.198-65%-2.546-3.314+30%-1.471-42%-2.151-16%44812.130-100%26441.838-100%
Price To Total Gains Ratio-30.154-65%-18.288-26.856+47%-7.237-60%-13.404-27%-26.193+43%-444.549+2331%
Quick Ratio--0.1690.099+71%0.359-53%0.812-79%57.485-100%85229.875-100%
Return On Assets---0.726-1.269+75%-0.804+11%-0.800+10%-0.868+20%-0.579-20%
Return On Equity----0%-0%-0.1240%-1.3500%-0.9010%
Total Gains Per Share---0.112-0.146+30%-0.217+93%-0.163+45%-0.046-59%-0.024-79%
Usd Book Value---25161000.000-21399250.000-15%-8956750.000-64%-6013750.000-76%-757702.234-97%15356043.881-264%
Usd Book Value Change Per Share---0.112-0.146+30%-0.217+93%-0.163+45%-0.084-25%-0.049-57%
Usd Book Value Per Share---1.455-1.238-15%-0.281-81%-0.444-69%-0.213-85%0.776-288%
Usd Dividend Per Share----0%-0%-0%0.037-100%0.025-100%
Usd Enterprise Value--8239860.00012213624.000-33%13361235.638-38%27740670.599-70%209626735.470-96%2497284900.012-100%
Usd Eps---0.319-0.349+9%-0.156-51%-0.209-34%-0.544+71%-0.365+14%
Usd Free Cash Flow---3480000.000-2847250.000-18%-4808750.000+38%-5508250.000+58%-5796026.881+67%-3902068.985+12%
Usd Free Cash Flow Per Share---0.201-0.165-18%-0.103-49%-0.134-33%-0.131-35%-0.090-55%
Usd Free Cash Flow To Equity Per Share--0.2370.048+400%-0.084+135%-0.042+118%-0.062+126%0.016+1404%
Usd Market Cap58437496.000+39%35442860.00036220874.000-2%25877235.638+37%37934837.265-7%215114446.966-84%202440723.178-82%
Usd Price Per Share3.380+39%2.0502.095-2%0.419+389%1.097+87%6.117-66%7.492-73%
Usd Profit---5512000.000-6027500.000+9%-6409750.000+16%-6791833.333+23%-9595150.050+74%-6384066.860+16%
Usd Revenue--4000.0002000.000+100%4000.0000%2000.000+100%1200.000+233%800.000+400%
Usd Total Gains Per Share---0.112-0.146+30%-0.217+93%-0.163+45%-0.046-59%-0.024-79%
 EOD+6 -2MRQTTM+18 -18YOY+17 -183Y+16 -215Y+15 -2410Y+14 -25

3.3 Fundamental Score

Let's check the fundamental score of NRX Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.650
Price to Book Ratio (EOD)Between0-1-2.323
Net Profit Margin (MRQ)Greater than0-1,378.000
Operating Margin (MRQ)Greater than0-2,269.500
Quick Ratio (MRQ)Greater than10.169
Current Ratio (MRQ)Greater than10.222
Debt to Asset Ratio (MRQ)Less than14.315
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.726
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of NRX Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.638
Ma 20Greater thanMa 503.340
Ma 50Greater thanMa 1002.737
Ma 100Greater thanMa 2002.459
OpenGreater thanClose3.300
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About NRX Pharmaceuticals Inc

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

Fundamental data was last updated by Penke on 2025-06-19 13:37:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ NRX Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ NRX Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -137,800.0%Β means thatΒ $-1,378.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NRX Pharmaceuticals Inc:

  • The MRQ is -137,800.0%. The company is making a huge loss. -2
  • The TTM is -91,187.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-137,800.0%TTM-91,187.5%-46,612.5%
TTM-91,187.5%YOY-33,937.5%-57,250.0%
TTM-91,187.5%5Y-25,025.0%-66,162.5%
5Y-25,025.0%10Y-16,683.3%-8,341.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-137,800.0%-91.7%-137,708.3%
TTM-91,187.5%-139.0%-91,048.5%
YOY-33,937.5%-194.4%-33,743.1%
3Y-41,708.3%-248.5%-41,459.8%
5Y-25,025.0%-343.3%-24,681.7%
10Y-16,683.3%-488.9%-16,194.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ NRX Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ NRX Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -72.6% Return on Assets means thatΒ NRX Pharmaceuticals Inc generatedΒ $-0.73 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NRX Pharmaceuticals Inc:

  • The MRQ is -72.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -126.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-72.6%TTM-126.9%+54.3%
TTM-126.9%YOY-80.4%-46.5%
TTM-126.9%5Y-86.8%-40.1%
5Y-86.8%10Y-57.9%-29.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-72.6%-11.6%-61.0%
TTM-126.9%-11.7%-115.2%
YOY-80.4%-11.4%-69.0%
3Y-80.0%-11.9%-68.1%
5Y-86.8%-12.1%-74.7%
10Y-57.9%-13.8%-44.1%
4.3.1.3. Return on Equity

Shows how efficient NRX Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ NRX Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means NRX Pharmaceuticals Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-135.0%+135.0%
5Y-135.0%10Y-90.1%-45.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.5%+13.5%
TTM--15.0%+15.0%
YOY--14.5%+14.5%
3Y-12.4%-16.9%+4.5%
5Y-135.0%-17.9%-117.1%
10Y-90.1%-19.9%-70.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of NRX Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient NRX Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit NRX Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ NRX Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of -226,950.0%Β means the company generated $-2,269.50 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NRX Pharmaceuticals Inc:

  • The MRQ is -226,950.0%. The company is operating very inefficient. -2
  • The TTM is -113,475.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-226,950.0%TTM-113,475.0%-113,475.0%
TTM-113,475.0%YOY-33,583.8%-79,891.2%
TTM-113,475.0%5Y-29,411.8%-84,063.2%
5Y-29,411.8%10Y-19,607.8%-9,803.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-226,950.0%-229.2%-226,720.8%
TTM-113,475.0%-249.7%-113,225.3%
YOY-33,583.8%-208.4%-33,375.4%
3Y-49,019.6%-221.7%-48,797.9%
5Y-29,411.8%-344.1%-29,067.7%
10Y-19,607.8%-470.4%-19,137.4%
4.3.2.2. Operating Ratio

Measures how efficient NRX Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 962.25 means that the operating costs are $962.25 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 962.250. The company is inefficient in keeping operating costs low. -1
  • The TTM is 392.688. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ962.250TTM392.688+569.563
TTM392.688YOY325.125+67.563
TTM392.6885Y143.563+249.125
5Y143.56310Y95.708+47.854
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ962.2502.108+960.142
TTM392.6882.680+390.008
YOY325.1253.080+322.045
3Y239.2713.621+235.650
5Y143.5634.734+138.829
10Y95.7086.546+89.162
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of NRX Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if NRX Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.22Β means the company has $0.22 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.222. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.195. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.222TTM0.195+0.026
TTM0.195YOY0.523-0.327
TTM0.1955Y1.114-0.918
5Y1.11410Y1.182-0.069
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2223.659-3.437
TTM0.1953.834-3.639
YOY0.5234.141-3.618
3Y1.0984.661-3.563
5Y1.1145.756-4.642
10Y1.1826.151-4.969
4.4.3.2. Quick Ratio

Measures if NRX Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ NRX Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.17Β means the company can pay off $0.17 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.169. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.099. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.169TTM0.099+0.070
TTM0.099YOY0.359-0.259
TTM0.0995Y57.485-57.385
5Y57.48510Y85,229.875-85,172.390
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1692.799-2.630
TTM0.0993.143-3.044
YOY0.3593.794-3.435
3Y0.8124.307-3.495
5Y57.4855.707+51.778
10Y85,229.8756.457+85,223.418
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of NRX Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of NRX Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ NRX Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 4.32Β means that NRX Pharmaceuticals Inc assets areΒ financed with 431.5% credit (debt) and the remaining percentage (100% - 431.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 4.315. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 5.347. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ4.315TTM5.347-1.032
TTM5.347YOY2.550+2.797
TTM5.3475Y1.955+3.392
5Y1.95510Y1.353+0.602
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3150.324+3.991
TTM5.3470.347+5.000
YOY2.5500.329+2.221
3Y2.8210.340+2.481
5Y1.9550.349+1.606
10Y1.3530.379+0.974
4.5.4.2. Debt to Equity Ratio

Measures ifΒ NRX Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ NRX Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.739-0.739
5Y0.73910Y0.928-0.190
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.379-0.379
TTM-0.435-0.435
YOY-0.412-0.412
3Y0.2700.446-0.176
5Y0.7390.460+0.279
10Y0.9280.509+0.419
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings NRX Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ NRX Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -1.61 means the investor is paying $-1.61Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NRX Pharmaceuticals Inc:

  • The EOD is -2.650. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.608. Based on the earnings, the company is expensive. -2
  • The TTM is -2.123. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.650MRQ-1.608-1.043
MRQ-1.608TTM-2.123+0.515
TTM-2.123YOY-1.109-1.014
TTM-2.1235Y-76.368+74.245
5Y-76.36810Y-963.350+886.982
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.650-2.282-0.368
MRQ-1.608-2.062+0.454
TTM-2.123-2.541+0.418
YOY-1.109-3.722+2.613
3Y-1.660-3.754+2.094
5Y-76.368-6.100-70.268
10Y-963.350-6.653-956.697
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NRX Pharmaceuticals Inc:

  • The EOD is -4.198. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.546. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.314. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.198MRQ-2.546-1.652
MRQ-2.546TTM-3.314+0.768
TTM-3.314YOY-1.471-1.843
TTM-3.3145Y44,812.130-44,815.444
5Y44,812.13010Y26,441.838+18,370.292
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.198-3.101-1.097
MRQ-2.546-2.689+0.143
TTM-3.314-3.594+0.280
YOY-1.471-4.363+2.892
3Y-2.151-5.065+2.914
5Y44,812.130-8.478+44,820.608
10Y26,441.838-9.273+26,451.111
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ NRX Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -1.41 means the investor is paying $-1.41Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NRX Pharmaceuticals Inc:

  • The EOD is -2.323. Based on the equity, the company is expensive. -2
  • The MRQ is -1.409. Based on the equity, the company is expensive. -2
  • The TTM is -1.723. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.323MRQ-1.409-0.914
MRQ-1.409TTM-1.723+0.315
TTM-1.723YOY-4.970+3.247
TTM-1.7235Y63.892-65.615
5Y63.89210Y46.243+17.649
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.3231.932-4.255
MRQ-1.4091.848-3.257
TTM-1.7232.119-3.842
YOY-4.9702.469-7.439
3Y-14.0712.526-16.597
5Y63.8923.667+60.225
10Y46.2434.351+41.892
4.6.2. Total Gains per Share

2.4. Latest News of NRX Pharmaceuticals Inc

Does NRX Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from NRX Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-20
22:52
NRx Pharmaceuticals files $150M mixed shelf offeringRead
2025-06-20
22:32
New to The Street Show #673 Airs Nationwide on Bloomberg TV - Saturday, June 21 at 6:30 PM EST Featuring FLOKI, NRX Pharmaceuticals (NASDAQ:NRXP), MUSQ - The Music ETF (NYSE:MUSQ), Health In Tech (NASRead
2025-06-14
16:36
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ:Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NRX Pharmaceuticals Inc.

4.8.1. Institutions holding NRX Pharmaceuticals Inc

Institutions are holding 13.077% of the shares of NRX Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Anson Funds Management LP6.81960.43981179061993401535.0646
2025-03-31Vanguard Group Inc2.2495038892514860961.839
2025-03-31AdvisorShares Investments, LLC1.65880.109286797-23517-7.5785
2025-03-31Geode Capital Management, LLC0.778901346576040681.3538
2025-03-31Marshall Wace Asset Management Ltd0.51530.000289086890860
2025-03-31State Street Corp0.252904372427000161.4446
2025-03-31Two Sigma Investments LLC0.17440.000130146301460
2025-03-31BlackRock Inc0.168202907500
2025-03-31Northern Trust Corp0.1654028601286010
2025-03-31One Wealth Management Investment & Advisory Services LLC0.0870.05111504100
2024-12-31TOWNSQUARE CAPITAL LLC0.0870.00041504100
2024-12-31Sassicaia Capital Advisers LLC0.08680.797815000150000
2025-03-31Morgan Stanley - Brokerage Accounts0.06880118967500170.6096
2025-03-31Bank of America Corp0.019303343451.3645
2024-12-31Wells Fargo & Co0.012502160-500-18.797
2025-03-31SBI Securities Co Ltd0.01160.0001200020000
2025-03-31SIMPLEX TRADING, LLC0.00370633-368-36.7632
2024-12-31UBS Group AG0.00090150112294.7368
2025-03-31Advisor Group Holdings, Inc.0.000509000
2025-03-31Carolina Wealth Advisors, LLC0.00030.00015000
Total 13.16141.39862275476+1377521+60.5%

4.9.2. Funds holding NRX Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-30AdvisorShares Psychedelics ETF1.72247.915629779700
2025-04-30Vanguard Total Stock Mkt Idx Inv1.4562025176000
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.07510.00041858804871535.5156
2025-04-30Fidelity Extended Market Index0.43520.000475244-720-0.9478
2025-04-30Fidelity Series Total Market Index0.11180.000119335736361.5018
2025-04-30Fidelity Total Market Index0.106301837500
2025-04-30Spartan Extended Market Index Pool F0.09090.0005157147204.8019
2025-03-31NT Ext Equity Mkt Idx Fd - L0.08840.00041528811470300.4191
2025-03-31Northern Trust Extended Eq Market Idx0.08840.00041528811470300.4191
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.07480.0004129379662295.0229
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05830.0004100717475287.943
2025-04-30Spartan Total Market Index Pool G0.05030.00018693274346.1008
2025-03-31Extended Equity Market Fund K0.02910.00015026150.2993
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.02120.000436722762303.5165
2025-05-31State St US Extended Mkt Indx NL Cl C0.00540.000193000
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.00530.00019109100
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.00530.00019109100
2025-03-31BNYM Mellon SL Market Completion UC10.00450.0004783-3-0.3817
2025-03-31Extended Equity Market Fund M0.00360.0001629-21-3.2308
2025-04-30JHVIT Total Stock Market Index I0.00230.00013923920
Total 5.43487.9201939634+103863+11.1%

5.3. Insider Transactions

Insiders are holding 15.883% of the shares of NRX Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-12-17Jonathan C JavittBUY400001.17
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Net Debt  5,4601,2366,696-1,6735,0231115,134-10,682-5,548



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets7,590
Total Liabilities32,751
Total Stockholder Equity-25,161
 As reported
Total Liabilities 32,751
Total Stockholder Equity+ -25,161
Total Assets = 7,590

Assets

Total Assets7,590
Total Current Assets7,256
Long-term Assets334
Total Current Assets
Cash And Cash Equivalents 5,548
Other Current Assets 1,708
Total Current Assets  (as reported)7,256
Total Current Assets  (calculated)7,256
+/-0
Long-term Assets
Long-term Assets Other 334
Long-term Assets  (as reported)334
Long-term Assets  (calculated)334
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities32,751
Long-term Liabilities5,011
Total Stockholder Equity-25,161
Total Current Liabilities
Short-term Debt 1,566
Short Long Term Debt 8,397
Accounts payable 4,311
Other Current Liabilities 24,129
Total Current Liabilities  (as reported)32,751
Total Current Liabilities  (calculated)38,403
+/- 5,652
Long-term Liabilities
Long-term Liabilities  (as reported)5,011
Long-term Liabilities  (calculated)0
+/- 5,011
Total Stockholder Equity
Common Stock17
Retained Earnings -283,785
Other Stockholders Equity 258,607
Total Stockholder Equity (as reported)-25,161
Total Stockholder Equity (calculated)-25,161
+/-0
Other
Capital Stock17
Cash and Short Term Investments 5,548
Common Stock Shares Outstanding 16,410
Liabilities and Stockholders Equity 7,590
Net Debt -5,548
Net Invested Capital -16,764
Net Working Capital -25,495
Short Long Term Debt Total 6,577



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
> Total Assets 
174
69,566
69,553
69,699
69,885
70,796
71,708
50,103
41,685
32,075
6,273
6,277
6,032
6,050
6,028
18,547
45,250
32,729
43,601
32,433
24,824
25,816
21,780
19,809
13,110
7,315
3,788
5,264
4,462
3,651
7,590
7,5903,6514,4625,2643,7887,31513,11019,80921,78025,81624,82432,43343,60132,72945,25018,5476,0286,0506,0326,2776,27332,07541,68550,10371,70870,79669,88569,69969,55369,566174
   > Total Current Assets 
82
536
335
216
124
30
51
41
208
1
1
37
3
82
60
18,534
45,234
32,714
43,584
32,414
24,801
25,795
21,756
19,788
13,089
6,884
3,347
4,880
4,106
3,302
7,256
7,2563,3024,1064,8803,3476,88413,08919,78821,75625,79524,80132,41443,58432,71445,23418,53460823371120841513012421633553682
       Cash And Cash Equivalents 
82
449
267
140
77
11
2
1
194
1
-1
0
1
0
0
13,386
38,884
27,605
40,202
24,548
18,249
20,054
16,506
14,969
8,902
4,595
1,319
1,898
1,646
1,443
5,548
5,5481,4431,6461,8981,3194,5958,90214,96916,50620,05418,24924,54840,20227,60538,88413,3860010-1119412117714026744982
       Short-term Investments 
0
69,029,443
69,029,443
0
0
70,766
71,657
50,061
41,477
32,005
2
6,240
5,935
0
5,968
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000005,96805,9356,240232,00541,47750,06171,65770,7660069,029,44369,029,4430
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
831
0
0
0
0
554
547
7
6
6
6
6
6
6
6
0
0
0066666667547554000083100000000000000
       Other Current Assets 
0
87
68
76
47
19
49
40
14
0
0
37
2
0
59
5,148
6,351
5,109
3,382
7,312
6,552
5,741
5,250
4,813
4,181
2,289
2,022
2,976
2,454
1,859
1,708
1,7081,8592,4542,9762,0222,2894,1814,8135,2505,7416,5527,3123,3825,1096,3515,1485902370014404919477668870
   > Long-term Assets 
91
69,029
69,218
69,483
69,761
70,766
71,657
50,061
41,477
32,005
6,192
6,240
5,935
0
5,968
13
16
15
17
19
23
21
24
21
21
431
441
384
356
349
334
334349356384441431212124212319171516135,96805,9356,2406,19232,00541,47750,06171,65770,76669,76169,48369,21869,02991
       Long-term Assets Other 
91
0
218
483
-239
-234
-343
61
477
5
192
240
-65
0
11
13
16
15
17
19
23
21
24
21
21
431
441
384
356
349
334
33434935638444143121212421231917151613110-65240192547761-343-234-239483218091
> Total Liabilities 
150
64,566
65
217
376
1,257
1,981
2,108
2,434
6
2,497
2,651
6
3,937
4,808
35,984
36,283
11,923
11,912
7,081
8,042
18,407
22,064
22,617
19,327
19,048
18,857
23,655
23,284
26,874
32,751
32,75126,87423,28423,65518,85719,04819,32722,61722,06418,4078,0427,08111,91211,92336,28335,9844,8083,93762,6512,49762,4342,1081,9811,2573762176564,566150
   > Total Current Liabilities 
150
93
65
217
376
567
494
521
642
2
316
297
5
610
644
35,472
36,283
11,923
11,912
7,081
8,042
15,585
22,064
22,617
19,327
19,048
18,857
23,655
20,299
21,863
32,751
32,75121,86320,29923,65518,85719,04819,32722,61722,06415,5858,0427,08111,91211,92336,28335,472644610529731626425214945673762176593150
       Short-term Debt 
100
0
0
0
0
0
0
0
0
0
0
0
1,693
0
1,965
174
515
518
520
0
0
7,703
12,189
12,692
10,069
9,161
6,779
8,594
3,684
1,566
1,566
1,5661,5663,6848,5946,7799,16110,06912,69212,1897,703005205185151741,96501,69300000000000100
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
174
515
518
520
0
0
7,703
12,189
12,692
10,069
9,161
6,779
7,651
3,684
1,566
8,397
8,3971,5663,6847,6516,7799,16110,06912,69212,1897,70300520518515174000000000000000
       Accounts payable 
100
86
61
204
328
551
446
432
537
2
313
0
3
0
4
6,268
5,559
3,687
4,311
3,078
2,168
2,076
3,776
2,205
3,631
4,632
6,265
5,015
4,866
4,130
4,311
4,3114,1304,8665,0156,2654,6323,6312,2053,7762,0762,1683,0784,3113,6875,5596,268403031325374324465513282046186100
       Other Current Liabilities 
50
8
4
13
48
16
48
89
104
551
3
294
-3
0
-4
29,030
30,209
7,718
7,081
4,003
5,874
5,806
6,099
7,720
5,627
5,255
5,813
10,046
11,749
16,167
24,129
24,12916,16711,74910,0465,8135,2555,6277,7206,0995,8065,8744,0037,0817,71830,20929,030-40-3294355110489481648134850
   > Long-term Liabilities 
0
85,671
64,488
64,482
64,510
690
1,487
1,587
1,792
3
2,181
2,354
1
0
4,164
512
0
4,205
7,601
4,003
5,874
2,822
3,776
0
0
0
12,592
18,640
2,985
5,011
5,011
5,0115,0112,98518,64012,5920003,7762,8225,8744,0037,6014,20505124,164012,3542,18131,7921,5871,48769064,51064,48264,48885,6710
> Total Stockholder Equity
24
5,000
69,488
69,482
69,510
69,539
69,727
47,995
39,251
-5
-5
3,626
-3
2,114
1,220
-17,437
8,967
20,806
31,689
25,352
16,782
7,409
-284
-2,808
-6,217
-11,733
-15,069
-18,391
-18,822
-23,223
-25,161
-25,161-23,223-18,822-18,391-15,069-11,733-6,217-2,808-2847,40916,78225,35231,68920,8068,967-17,4371,2202,114-33,626-5-539,25147,99569,72769,53969,51069,48269,4885,00024
   Common Stock
2
3
64,491
64,484
64,512
64,541
64,730
42,998
34,254
0
3
3
0
3
3
49
55
59
67
67
68
67
70
80
84
84
10
11
11
15
17
1715111110848480706768676759554933033034,25442,99864,73064,54164,51264,48464,49132
   Retained Earnings 
-1
-105
-90
-96
-68
-39
149
325
384
-38
643
493
-45
-720
-1,614
-131,677
-152,450
-183,243
-196,691
-203,673
-212,756
-222,997
-234,036
-242,753
-248,815
-253,147
-259,675
-267,572
-269,195
-278,273
-283,785
-283,785-278,273-269,195-267,572-259,675-253,147-248,815-242,753-234,036-222,997-212,756-203,673-196,691-183,243-152,450-131,677-1,614-720-45493643-38384325149-39-68-96-90-105-1
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
3,130
3,130
2,831
2,831
2,831
114,191
161,362
0
228,313
0
229,470
0
233,576
239,887
0
0
0
0
0
0
0
0000000239,887233,5760229,4700228,3130161,362114,1912,8312,8312,8313,1303,1300000000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
23
5,102
5,087
5,094
5,065
5,036
4,848
4,672
4,613
5,028
3,776
3,130
-12,078
0
2,831
114,191
161,362
203,990
228,313
228,958
229,470
230,339
233,576
239,887
242,533
241,330
244,599
249,173
250,362
255,035
258,607
258,607255,035250,362249,173244,599241,330242,533239,887233,576230,339229,470228,958228,313203,990161,362114,1912,8310-12,0783,1303,7765,0284,6134,6724,8485,0365,0655,0945,0875,10223



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-5
Gross Profit0-5
 
Operating Income (+$)
Gross Profit0
Operating Expense-19,704
Operating Income-18,502-19,704
 
Operating Expense (+$)
Research Development6,199
Selling General Administrative13,505
Selling And Marketing Expenses0
Operating Expense19,70419,704
 
Net Interest Income (+$)
Interest Income44
Interest Expense-230
Other Finance Cost-0
Net Interest Income-186
 
Pretax Income (+$)
Operating Income-18,502
Net Interest Income-186
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-25,126-11,878
EBIT - interestExpense = -18,737
-25,126
-24,896
Interest Expense230
Earnings Before Interest and Taxes (EBIT)-18,507-24,896
Earnings Before Interest and Taxes (EBITDA)-18,502
 
After tax Income (+$)
Income Before Tax-25,126
Tax Provision-0
Net Income From Continuing Ops-25,126-25,126
Net Income-25,126
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses19,704
Total Other Income/Expenses Net-6,624186
 

Technical Analysis of NRX Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of NRX Pharmaceuticals Inc. The general trend of NRX Pharmaceuticals Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine NRX Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. NRX Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NRX Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.53 < 3.8286 < 6.

The bearish price targets are: 3 > 2.9001 > 2.41.

Know someone who trades $NRXP? Share this with them.πŸ‘‡

NRX Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NRX Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NRX Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NRX Pharmaceuticals Inc. The current macd is 0.15095729.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the NRX Pharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for NRX Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the NRX Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
NRX Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartNRX Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NRX Pharmaceuticals Inc. The current adx is 27.88.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy NRX Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
NRX Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NRX Pharmaceuticals Inc. The current sar is 3.5601354.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
NRX Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NRX Pharmaceuticals Inc. The current rsi is 58.64. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
NRX Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartNRX Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NRX Pharmaceuticals Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the NRX Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
NRX Pharmaceuticals Inc Daily Stochastic Oscillator ChartNRX Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NRX Pharmaceuticals Inc. The current cci is 2.97915402.

NRX Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartNRX Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NRX Pharmaceuticals Inc. The current cmo is 13.97.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
NRX Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartNRX Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NRX Pharmaceuticals Inc. The current willr is -32.38940547.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that NRX Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
NRX Pharmaceuticals Inc Daily Williams %R ChartNRX Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NRX Pharmaceuticals Inc. The current atr is 0.23475179.

NRX Pharmaceuticals Inc Daily Average True Range (ATR) ChartNRX Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NRX Pharmaceuticals Inc. The current obv is 35,476,081.

NRX Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartNRX Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NRX Pharmaceuticals Inc. The current mfi is 37.67.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
NRX Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartNRX Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NRX Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

NRX Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NRX Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.638
Ma 20Greater thanMa 503.340
Ma 50Greater thanMa 1002.737
Ma 100Greater thanMa 2002.459
OpenGreater thanClose3.300
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of NRX Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on NRX Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about NRX Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NRX Pharmaceuticals Inc

I send you an email if I find something interesting about NRX Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NRX Pharmaceuticals Inc.

Receive notifications about NRX Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.